Pricing

Gracell Biotechnologies Inc. ADR (GRCL)

followers ·
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Wei Cao
Employees: 350
Web site: gracellbio.com
BUILDING 3, 418 GUILIN ROAD, XUHUI DISTRICT, SHANGHAI, F4, 200030
00862164031522

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

All 13F Filers Prior Change Hedge Funds 1 Prior Change
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate. GC019F is in Phase I clinical trial for the. treatment of adult B cell acute lymphoblastic leukemia (B-ALL)
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available